Dr. Runaas is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9200 W Wisconsin Ave
Milwaukee, WI 53226Phone+1 414-805-4600Fax+1 414-805-6815
Education & Training
University of MichiganFellowship, Hematology and Medical Oncology, 2014 - 2017
University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 2010 - 2013
University of Wisconsin School of Medicine & Public HealthClass of 2010
Certifications & Licensure
WI State Medical License 2012 - 2025
MI State Medical License 2014 - 2018- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease Start of enrollment: 2020 Mar 01
Publications & Presentations
PubMed
- 4 citationsA phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia.Guru Subramanian Guru Murthy, Antoine N Saliba, Aniko Szabo, Alexandra Harrington, Sameem Abedin
Haematologica. 2024-09-01 - Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention.Fateeha Furqan, Vineel Bhatlapenumarthi, Binod Dhakal, Timothy S Fenske, Faiqa Farrukh
Blood Advances. 2024-08-27 - 1 citationsSeverity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogen...Saurabh Chhabra, James H Jerkins, Kathleen Monahan, Aniko Szabo, Nirav N Shah
Bone Marrow Transplantation. 2024-03-01
Abstracts/Posters
- A Multisite Phase Ib Study of Pevonedistat, Azacitidine and Venetoclax (PAVE) for the Treatment of Subjects with Acute Myelogenous Leukemia (AML)Lyndsey Runaas, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Lintuzumab Ac-225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML: Interim Results of a Phase I StudyLyndsey Runaas, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Systematic Screening for Familial Leukemia Based on Somatic Genomic Profiling Results2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Reducing Venous Thrombosis with Antithrombin Supplementation in Patients Undergoing Treatment for ALL with Asparaginase Based Regimens2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
